Eloxx Presents More Positive Preclinical Data for ELX-02, Potential CF Treatment
Eloxx Pharmaceuticals presented new positive preclinical data for ELX-02, its lead treatment candidate for cystic fibrosis (CF), demonstrating that the therapy increases the levels of CFTR protein and its correct placement at the cell’s surface in patient-derived organoids. Findings were presented by Shira Landskroner-Eiger, PhD, Eloxx’s principal…